Brian Garrison
Vice President of Research Senti Bio
Dr. Garrison joined Senti Bio in 2016, where he has continually applied his 25 years of cell & gene therapy experience towards the successful development and clinical application of Senti’s Gene Circuit technologies to develop truly innovative medicines with the ability to target diseases in a more focused, controlled, and effective manner. Dr. Garrison currently leads both the Discovery Research and Translational Science Teams at Senti.
Dr. Garrison earned his B.S. in Microbiology (minor: Comparative Literature) from University of California, Davis, and a Ph.D. in human gene therapy from Stanford University, then completed 2 postdoctoral fellowships (Harvard University & Harvard Medical School) focused on stem cell biology, leukemia, genome editing, and TGFβ, with numerous high impact publications, fellowship, grant, and contract awards.
Seminars
- Will present clinical data consistent with SENTI-202 mechanism of action, including:
- CD33 OR FLT3 logic gated CAR approach for targeting both AML blasts and leukemic stem cell NOT EMCN logic gated inhibitory CAR approach for protection of hematopoietic stem and progenitor cells
- Supporting data for SENTI-202 PK, patient disease characterization, and patient responses
Advancing NK-based therapies from preclinical proof-of-concept to meaningful clinical outcomes depends on identifying the right patients and monitoring their responses effectively. Predictive biomarkers, translational analytics, and innovative assay platforms are critical to reduce trial risk, guide dosing, and validate therapeutic mechanisms. This workshop explores state-of-the-art strategies to integrate biomarker discovery and translational science into NK therapy development to de-risk programs and speed regulatory and clinical milestones.
Join this workshop to:
- Understand emerging biomarkers for patient selection, persistence, and therapeutic response in autoimmunity and oncology
- Explore cutting-edge analytical tools, single-cell sequencing, spatial transcriptomics, and functional NK assays to uncover actionable insights
- Review case-based examples of how translational strategies can refine trial design, optimize dosing, and improve go/no-go decisions
